


RareAl Launches Free Al-Driven Platform and Consultancy Services to Assist Rare Disease Diagnosis and Treatment

New AI-Powered Tool and Complimentary Consultancy Provide Personalized Analysis and Treatment Options for Rare Disease Patients Worldwide

MIDDLETOWN, DE, UNITED STATES, March 20, 2025 /EINPresswire.com/ -- RareAl, a nonprofit organization dedicated to transforming healthcare for rare diseases, is proud to announce the launch of its free Rare Disease Research Assistant Platform, accessible at http://app.rareai.org. This innovative platform leverages artificial intelligence and decentralized science to provide affordable, personalized diagnostic and treatment solutions for individuals affected by rare diseases, who constitute approximately 4% of the global population.



In addition to the platform, RareAl now offers free consultancy services to assist patients and healthcare professionals in interpreting genetic data and exploring personalized treatment options. These services aim to bridge the gap between complex genetic information and practical medical applications, ensuring that patients receive the most effective care possible.

Rare diseases account for 35% of deaths in the first year of life and 30% of deaths in children before their fifth birthday. RareAl's mission is to cure the incurable and leave no patient behind. The newly launched platform offers a seamless four-step process designed to empower patients and healthcare professionals:

1. Input De-identified Genetic Report: Users can securely upload their de-identified genetic reports containing pathological gene variance information to the RareAl computational engine.

- 2. Analysis by RareAl Computational Engine: The platform's advanced machine learning algorithms analyze the genetic data to identify potential diagnoses and treatment options.
- 3. Personalized Medical Analysis Report: Upon completion of the analysis, users receive a comprehensive gene analysis report via email, detailing the findings and suggesting possible diagnoses and treatments.
- 4. Personalized Medicine Options: The report includes tailored medicine options, such as mRNA therapy, to assist healthcare professionals in customizing treatments based on the patient's unique genetic makeup.

RareAl's commitment to confidentiality ensures that all genetic information remains private and de-identified throughout the process. By harnessing the power of artificial intelligence and decentralized science, RareAl aims to revolutionize rare disease diagnosis and treatment, making quality healthcare accessible to all, regardless of their circumstances.

In recognition of its innovative approach and dedication to the rare disease community, RareAl was honored with the <u>#RAREis Global Advocate Grant</u> by Amgen in 2024. This grant supports advocacy organizations that advance, educate, and address the needs of the rare disease community.

Disclaimer: The RareAl platform and consultancy services are designed to assist in the interpretation of genetic data and provide information on potential diagnoses and treatment options. However, they are not a substitute for professional medical advice, diagnosis, or treatment. Users are advised to consult with qualified healthcare professionals before making any medical decisions based on the information provided by RareAl. RareAl does not assume any responsibility or liability for the accuracy or applicability of the information provided.

To support RareAl's mission and contribute to the advancement of rare disease research and treatment, donations can be made through our <u>Funraise</u> page. Your generous contributions will help us continue to provide free services and develop innovative solutions for the rare disease community.

For more information about RareAI, its free consultancy services from rare disease researchers, and its mission to improve healthcare access for rare disease patients, please visit https://rareai.org.

RareAl Institute is recognized by the IRS as a tax-exempt organization under Section 501(c)(3) of the Internal Revenue Code (EIN: 88-2336284).

Lurong Pan, PhD RareAl Institute +1 205-249-7424 lp@rareai.org Visit us on social media: LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/795613021

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.